Search Results - "Ramchand, Sabashini K"

The Influence of Cortical Porosity on the Strength of Bone During Growth and Advancing Age by Ramchand, Sabashini K., Seeman, Ego

“…Purpose of Review Bone densitometry provides a two-dimensional projected areal apparent bone mineral density that fails to capture the heterogeneity of bone’s…”
Get full text

Advances and Unmet Needs in the Therapeutics of Bone Fragility by Ramchand, Sabashini K, Seeman, Ego

“…The prevalence of fragility fractures increases as longevity increases the proportion of the elderly in the community. Until recently, the majority of studies…”
Get full text

Protocol: Can coronary artery calcium score identified on thoracic planning CT scans be used and actioned to identify cancer survivors at high risk of cardiac events: A feasibility study in cancer survivors undergoing radiotherapy in Australia by Dalla Via, Jack, Stewart, Nina, Kennedy, Mary A, Cehic, Daniel A, Purnell, Peter, Toohey, Joanne, Morton, Jamie, Ramchand, Sabashini K, Lewis, Joshua R, Zissiadis, Yvonne

“…IntroductionA coronary artery calcium (CAC) CT scan can identify calcified plaque and predict risk of future cardiac events. Cancer survivors undergoing…”
Get full text

Skeletal Effects of Adjuvant Zoledronic Acid and Its Cessation in Women with Early-Stage Breast Cancer by Ramchand, Sabashini K

Get full text

Higher maternal serum prolactin levels are associated with reduced glucose tolerance during pregnancy by Ekinci, Elif I, Torkamani, Niloufar, Ramchand, Sabashini K, Churilov, Leonid, Sikaris, Ken A, Lu, Zhong X, Houlihan, Christine A

“…It is unknown if high prolactin levels during pregnancy contribute to the development of gestational diabetes. We hypothesized that higher prolactin levels are…”
Get full text

Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis by Ramchand, Sabashini K, Leder, Benjamin Z

“…Osteoporosis is a chronic condition characterized by decreased bone mass, loss of skeletal integrity, and increased susceptibility to fracture. Drugs used to…”
Get full text

Reply to C. Fuchao et al by Ramchand, Sabashini K, Seeman, Ego, Hoermann, Rudolf, Ghasem-Zadeh, Ali, Grossmann, Mathis

Get full text

The effects of adjuvant endocrine therapy on bone health in women with breast cancer by Ramchand, Sabashini K, Cheung, Yee-Ming, Yeo, Belinda, Grossmann, Mathis

“…In women with oestrogen receptor (ER)-positive early breast cancer, oestradiol is important for breast cancer development and progression. Endocrine therapy…”
Get full text

Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension by Ramchand, Sabashini K, David, Natalie L, Lee, Hang, Eastell, Richard, Tsai, Joy N, Leder, Benjamin Z

“…ABSTRACT Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab…”
Get full text

The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial by Ramchand, Sabashini K., Tsai, Joy N., Lee, Hang, Sassana-Khadka, Grace, Jordan, Mackenzie, Ryan, Savannah, Leder, Benjamin Z.

“…Summary Denosumab discontinuation results in accelerated bone remodeling, decreased bone mineral density (BMD), and an increased risk of multiple vertebral…”
Get full text

Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial by Ramchand, Sabashini K., Tsai, Joy N., Lee, Hang, Sassana-Khadka, Grace, Jordan, Mackenzie, Ryan, Savannah, Leder, Benjamin Z.

Get full text

Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT by Ramchand, Sabashini K, Hoermann, Rudolf, White, Shane, Yeo, Belinda, Francis, Prudence A, Xu, Cecilia L H, Zajac, Jeffrey D, Seeman, Ego, Grossmann, Mathis

“…Abstract Context Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal…”
Get full text

Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed? by Ramchand, Sabashini K., Lim, Elgene, Grossmann, Mathis

“…Summary Adjuvant endocrine therapy provides oncological benefits in women with early oestrogen‐receptor‐positive breast cancer, but has adverse effects…”
Get full text

Evaluation of Osteogenic Phenotype in Postmenopausal Women Receiving Anabolic and Antiresorptive Osteoporosis Therapies by Kobelski, Margaret M, Ramchand, Sabashini K, Tsai, Joy N, Leder, Benjamin Z, Demay, Marie B

“…Abstract Aging of the general population has led to a substantial increase in the prevalence of osteoporosis over the past decades. While there are effective…”
Get full text

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension by Ramchand, Sabashini K., David, Natalie L., Lee, Hang, Bruce, Michael, Bouxsein, Mary L., Tsai, Joy N., Leder, Benjamin Z.

“…ABSTRACT The combination of denosumab and teriparatide is an effective treatment strategy in postmenopausal osteoporosis, though skeletal gains are promptly…”
Get full text

Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia by Grossmann, Mathis, Ramchand, Sabashini K., Milat, Frances, Vincent, Amanda, Lim, Elgene, Kotowicz, Mark A., Hicks, Jill, Teede, Helena

“…Summary To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor‐positive early breast cancer…”
Get full text

Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT by Ramchand, Sabashini K, David, Natalie L, Leder, Benjamin Z, Tsai, Joy N

“…Abstract Context In the Denosumab and High-Dose Teriparatide Administration (DATA-HD) study, we reported that 15 months of combined high-dose (HD) teriparatide…”
Get full text

Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial by Ramchand, Sabashini K, Ghasem-Zadeh, Ali, Hoermann, Rudolf, White, Shane, Yeo, Belinda, Francis, Prudence A, Xu, Cecilia L H, Coleman, Olivia, Shore-Lorenti, Cat, Ebeling, Peter R, Zajac, Jeffrey D, Seeman, Ego, Grossmann, Mathis

“…Suppression of ovarian function and aromatase inhibition (AI) increases disease-free survival in premenopausal women with estrogen receptor (ER)-positive…”
Get full text

Effects of Combination Denosumab and High‐Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA‐HD HR‐pQCT Study by Ramchand, Sabashini K, David, Natalie L, Lee, Hang, Bruce, Michael, Bouxsein, Mary L, Leder, Benjamin Z, Tsai, Joy N

“…ABSTRACT In postmenopausal women at high risk of fracture, we previously reported that combined denosumab and high‐dose (HD; 40 μg) teriparatide increased…”
Get full text

Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary by Grossmann, Mathis, Ramchand, Sabashini K, Milat, Frances, Vincent, Amanda, Lim, Elgene, Kotowicz, Mark A, Hicks, Jill, Teede, Helena J

“…Introduction Representatives appointed by relevant Australian medical societies used a systematic approach for adaptation of guidelines (ADAPTE) to formulate…”
Get full text